Abstract
The prevalence of diabetes is increasing, and patients with diabetes are at increased risk of adverse cardiovascular outcomes. Recently, the results from 11 large randomized clinical trials have suggested a difference in the emergence of new diabetes according to cardiovascular medication use. Treatment with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and calcium antagonists yielded a lower incidence of diabetes development than beta-blockers and diuretics. Physicians should consider this possible diabetes consequence when prescribing long-term beta-blockers and diuretics, particularly in patients at high risk of developing diabetes.
MeSH terms
-
Adrenergic beta-Antagonists / adverse effects
-
Angiotensin Receptor Antagonists
-
Angiotensin-Converting Enzyme Inhibitors / administration & dosage
-
Calcium Channel Blockers / administration & dosage
-
Cardiovascular Agents / administration & dosage*
-
Cardiovascular Agents / adverse effects*
-
Diabetes Mellitus / epidemiology
-
Diabetes Mellitus / prevention & control*
-
Diuretics / adverse effects
-
Humans
-
Incidence
-
Randomized Controlled Trials as Topic
-
Risk Factors
-
United States / epidemiology
Substances
-
Adrenergic beta-Antagonists
-
Angiotensin Receptor Antagonists
-
Angiotensin-Converting Enzyme Inhibitors
-
Calcium Channel Blockers
-
Cardiovascular Agents
-
Diuretics